Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been assigned an average recommendation of “Hold” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $5.50.

Several research analysts have issued reports on MRVI shares. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. UBS Group reissued a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Finally, Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th.

Maravai LifeSciences Trading Up 2.2%

Shares of Maravai LifeSciences stock opened at $6.26 on Friday. Maravai LifeSciences has a 1 year low of $1.99 and a 1 year high of $6.29. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91. The company has a market capitalization of $1.61 billion, a P/E ratio of -8.81 and a beta of 0.72. The company’s fifty day moving average is $4.53 and its two-hundred day moving average is $3.77.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. Analysts forecast that Maravai LifeSciences will post -0.2 earnings per share for the current year.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. increased its stake in Maravai LifeSciences by 2.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after buying an additional 178,445 shares during the period. Mackenzie Financial Corp increased its stake in Maravai LifeSciences by 1.7% in the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock valued at $20,148,000 after buying an additional 104,355 shares during the period. Renaissance Technologies LLC increased its stake in Maravai LifeSciences by 0.9% in the 1st quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock valued at $12,069,000 after buying an additional 39,600 shares during the period. Tejara Capital Ltd increased its stake in Maravai LifeSciences by 23.1% in the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after buying an additional 566,768 shares during the period. Finally, Geode Capital Management LLC increased its stake in Maravai LifeSciences by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock valued at $9,259,000 after buying an additional 34,447 shares during the period. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.